BioNetwork 2014 (past event)
27 - 29 October, 2014
Microsoft , Singapore, FL
The Ritz-Carlton, Laguna Niguel, CA
Day 3
08:00 - 08:45 Networking Breakfast
08:45 - 08:50 Welcoming Remarks
Sara Mueller, Executive Director, BioNetwork
08:50 - 09:00 Chairperson’s Opening Address
Miles Gerson
Managing Officer of Business DevelopmentUniversity of California at Los Angeles
09:00 - 09:35 One Successful Story: An Alliance Collaboration Through The Finish Line (From Phase 1 To Launch)
Monica Viziano
Senior Director of Alliance Management and Corporate DevelopmentGilead Sciences, Inc.
09:35 - 10:15 PANEL: Best Practices For Alternative M&A Financing, Including Structured And Contingent Value Right (CVR) Transactions
Speakers:
Syed Kazmi Executive Director, Strategy & Corporate Development Amgen
Kevin Finney Vice President of Business Development Allergan, Inc.
Miles Gerson Managing Officer of Business Development University of California at Los Angeles
Amit Hasija Vice President and Head of North American Pharmaceuticals Business Developm Sanofi
Syed Kazmi Executive Director, Strategy & Corporate Development Amgen
Kevin Finney Vice President of Business Development Allergan, Inc.
Miles Gerson Managing Officer of Business Development University of California at Los Angeles
Amit Hasija Vice President and Head of North American Pharmaceuticals Business Developm Sanofi
• With the trend over the last couple years towards moving away from traditional M&A, what other transactions are surfacing and working well?
• Explaining the deal framework of a CVR transaction
• Exploring how CVRs have been designed and negotiated between the buy side and the sell side, including what achievement milestones have been put in place
• Exploring a consultant’s role in arranging CVR agreements and how they have seen them shift over the last year or two
Miles Gerson
Managing Officer of Business DevelopmentUniversity of California at Los Angeles
Amit Hasija
Vice President and Head of North American Pharmaceuticals Business DevelopmSanofi
10:15 - 11:00 Networking And Refreshment Break
11:00 - 11:40 PANEL: Exploring Opportunities In Converging Drug-Device Technologies And Their Place In BioPharma Future
Speakers:
Paul Resnick Vice President of Business Development Juventas Therapeutics
David Maske Senior Manager of Business Development and Drug Delivery DSM Biomedical
Miles Gerson Managing Officer of Business Development University of California at Los Angeles
Chris Coletta Director, Drug Delivery Device Strategy Amgen
Francois Binette VP Research and Business Development OrthoCyte Corp. BioTime
Paul Resnick Vice President of Business Development Juventas Therapeutics
David Maske Senior Manager of Business Development and Drug Delivery DSM Biomedical
Miles Gerson Managing Officer of Business Development University of California at Los Angeles
Chris Coletta Director, Drug Delivery Device Strategy Amgen
Francois Binette VP Research and Business Development OrthoCyte Corp. BioTime
• Examining the current state of drug-device combination products and how the technology, regulatory processes, and purchasers are coming together
• Are drug-device combos rarities or are they truly the wave of the future? The commonality of emerging biologic-device combination and solutions
• Uncovering how the industry will need to shift to support drug-device convergence technologies and what biopharma can do to enable this innovation
• Stories from the trenches: from customer selection and staffing the organization, to building your team and how best to approach the buying universe when its time to sell
o Selection of proprietary vs. off-the-shelf solutions vs. combinations
Miles Gerson
Managing Officer of Business DevelopmentUniversity of California at Los Angeles
Chris Coletta
Director, Drug Delivery Device StrategyAmgen
11:40 - 00:20 PANEL: Examining The Changing Face Of Venture Capital
• How has traditional venture capital changed over the past year, and what are expectations for the near- and far-term future?
• Exploring the emergence of venture capital groups associated with large provider organizations; what are their objectives in the current biopharma space?
• Discovering how the relationship between large pharma and VC is evolving
Miles Gerson
Managing Officer of Business DevelopmentUniversity of California at Los Angeles
Bas van der Baan
Vice President Clinical Affairs & Business DevelopmentAgendia
00:20 - 23:59 Networking Luncheon And Close of BioNetwork 2014
Last chance for networking with your fellow BioNetwork attendees!